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Abstract
Background: LeptiCore® is a proprietary combination of various ingredients which have been shown to have
properties which could be beneficial to weight loss in obese and overweight human subjects. This study evaluates
the effect of Lepticore® on bodyweight as well as parameters associated with obesity and metabolic syndrome.
Methods: The study was an 8 week randomized, double-blind, placebo-controlled design involving 92 obese
(mean BMI > 30 kg/m
2) participants (37 males; 55 females; ages 19-52; mean age = 30.7). The participants were
randomly divided into three groups: placebo (n = 30), LeptiCore® formula A (low dose) (n = 31) and LeptiCore®
formula B (high dose) (n = 31). Capsules containing the placebo or active formulations were administered twice
daily before meals with 300 ml of water. None of the participants followed any specific diet nor took any weight-
reducing medications for the duration of the study. A total of 12 anthropomorphic and serological measurements
were taken at the beginning of the study and after 2, 4, 6, and 8 weeks of treatment.
Results: Compared to the placebo group, the two active groups showed statistically significant differences on all
12 variables by week 8. These included four anthropomorphic variables (body weight, body fat, waist and hip size)
and eight measures of serological levels (plasma total cholesterol, LDL, HDL, triglycerides, blood glucose, serotonin,
leptin, C-reactive protein). The two active groups also showed significant intra-group differences on all 12 variables
between study onset and week 8.
Conclusion: The LeptiCore® formulation at both the low and high dosages appears to be helpful in the
management of fat gain and its related complications. The higher dosage resulted in significantly greater
reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased
serotonin levels.
Background
Metabolic syndrome, a common disorder also known as
Syndrome X and insulin resistance syndrome is (like
many other obesity-related conditions) on the rise
throughout the world. The American Heart Association
criteria for metabolic syndrome include abdominal obe-
sity, atherogenic dyslipidemia, elevated blood pressure,
insulin resistance or glucose intolerance, prothrombotic
state, and pro-inflammatory state.
As of 2001, some 47 million people in the United
States had metabolic syndrome - which was projected to
overtake cigarette smoking as the greatest risk factor of
cardiovascular disease [1]. One of the accompanying
conditions of metabolic syndrome that has not received
as much attention is oxidative stress. This seems to be a
key in the disease condition, and all efforts to address
the independent components of metabolic syndrome
should include an effort to reduce oxidative stress,
which has not been clearly established to be a prelude
or consequence of metabolic syndrome.
In an effort to delay the onset of heart disease and
type 2 diabetes for the vast and ever-increasing numbers
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diseases, the current International Diabetes Foundation
recommends pharmacological agents that specifically
target individual components of metabolic syndrome
[2-7]. Although these agents can have benefits, the com-
bination of safety concerns, high costs, and the complex
nature of the condition have encouraged the investiga-
tion of medicinal plants as natural supplements in its
treatment.
LeptiCore® is a proprietary blend of plant-based poly-
saccharides, esterified fatty acids, pomegranate, polyphe-
nols and ellagic acid, beta carotene, and aphanizomenon
flosaquae extract, which are components shown to
reduce stored body fat, enhance weight loss, act as anti-
oxidants and ameliorate the symptoms of metabolic
syndrome.
Research has shown that leptin serves as a regulator of
body fat storage by modulating satiation, glycemic con-
trol and metabolism; and that reduction in serum leptin
correlates with lower regional body fat and total body
fat [8-10]. Leptin has also been shown to cause oxidative
stress [11], which can further exacerbate metabolic
syndrome.
Leptin is secreted by fat - the more fat, the more lep-
tin - yet it is named for the Greek word leptos, which
means “thin.” While obese people produce much higher
levels of leptin than thin and normal-weight individuals,
they are somehow resistant to its effects [8,12].
One reason for this may be that elevated levels of C-
reactive protein (CRP), which inhibits leptin’sr o l ei n
controlling appetite [13]. CRP is now considered a key
marker for low-grade systemic inflammation which, in
turn, is considered by leading scientists to be responsi-
ble for a number of metabolic problems that result in
unwanted weight gain and obesity [14]. Low grade,
internal, invisible inflammation, oxidative stress, along
with high leptin levels, may be a root cause of excess
body fat and the inability to lose excess or unwanted fat
[15].
In vivo and in vitro research done at the University of
Pittsburgh demonstrated that CRP binds to leptin
thereby impairing its signaling in two ways: 1) the cou-
pling of CRP to leptin makes crossing the blood-brain
barrier nearly impossible, thus preventing “free” leptin
access to the hypothalamus; 2) the CRP/leptin complex
inhibits the binding of leptin to its receptors, thus
blocking its ability to signal in cultured cells. Since
human CRP correlates with increased plasma leptin and
adiposity, the results “suggest a potential mechanism to
leptin resistance, by which circulating CRP binds to lep-
tin and attenuates its physiological functions [16].
In one set of studies, the researchers delivered human
leptin continuously for six days into mice which had
receptors for leptin but lacked the ability to produce it.
As expected, the plump mice ate less and lost weight,
and their blood glucose levels normalized. Infusions
containing both leptin and high doses of CRP, however,
blocked the action of leptin. The plump mice just kept
eating, getting fatter and fatter, and were no longer pro-
tected against diabetes. Giving CRP alone affected
neither food intake nor body weight [16].
Another experiment showed that human liver cells
increased CRP expression when exposed to leptin,
which suggests that appetite may be regulated through a
feedback loop that includes the liver in addition to the
brain and leptin-secreting fat cells [16].
Of the various ingredients in the LeptiCore formula-
tion, the plant-based polysaccharides and esterified fatty
acids have been shown to lower leptin level, resulting in
reduced appetite and weight loss [17,18]. Various studies
have shown that pomegranate extract contains polyphe-
nolic compounds and beta carotenes, which have con-
siderable efficacy in lowering CRP, resulting in reduced
inflammation and lowered cholesterol [19-21]. The
reduction of inflammation and CRP promotes leptin’s
effectiveness, increasing the possibility of reduced appe-
tite and weight loss. These components have also been
shown to be effective antioxidants which will conse-
quently improve the components of metabolic
syndrome.
The last of the natural ingredients in this formulation,
the phycocyanamines (blue green algae–ah i g hp h e n y -
lethylamine (PEA) blend) addresses the emotional
aspects of metabolic syndrome by increasing the vital
neurotransmitter, serotonin (5-HT), a well known mood
elevator [22,23]. Many studies have shown that seroto-
nin affects eating behavior and body weight, and that
increased serotonin plasma levels are associated with
decreased food intake, reduced weight gain, and
increased energy expenditure [24,25].
The primary purpose of the present study was to
determine the effects of two dosage levels of a unique,
natural formulation containing the above agents on
weight loss in patients with metabolic syndrome.
Methods
Participants
Ninety two obese participants were recruited for the
8-week study. Based on physical examination by a physi-
cian and laboratory screening tests, all participants met
the American Heart Association criteria for metabolic
syndrome, which include abdominal obesity, atherogenic
dyslipidemia, elevated blood pressure, insulin resistance
or glucose intolerance, prothrombotic state, and pro-
inflammatory state.
Specific inclusion criteria included: BMI > 30 kg/m
2;
total cholesterol >200 mg/dl; LDL cholesterol >160 mg/
dl; HDL cholesterol <40 mg/dl; triglycerides >150 mg/dl;
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>130/85 mmHg.
Specific exclusion criteria included: morbid obesity
(BMI > 40 kg/m
2); diabetes mellitus requiring daily insu-
lin management; pregnancy/lactation; active infection;
and systemic disease such as HIV/AIDS, active hepatitis
or clinical signs of active malignancy within the past 5
years. Other exclusion criteria included the use of any
cholesterol-lowering medications 30 days prior to enrol-
ling in the study and/or medication (e.g., steroids) that
interfere with healing; and enrolment in another clinical
study within the past 6 months.
Of the 92 subjects, 37 were male and 55 were female.
The age range was 19-52 (mean age = 30.7), and the
mean BMI was > 30 kg/m
2.
The purpose, nature and potential risks of the study
were explained to all patients and all gave a written
informed consent before participation. The Cameroon
National Ethics Committee approved the protocol. The
study was conducted in accordance with the Helsinki
Declaration (1983 version). None of the participants
took any weight-reducing medication nor followed any
specific diet during the duration of the study.
Study design/Intervention
The study was a randomized, double-blind, placebo-con-
trolled design. Participants were randomly divided into
three groups: placebo, LeptiCore® formula A (low dose)
and LeptiCore® formula B (high dose). The placebo or
active formulations were administered twice daily before
meals with approximately 300 ml (8-10 oz.) of water.
Formula A = 1 capsule (300 mg each); Formula B = 2
capsules (300 mg each). Since the active and placebo
capsules were identical in shape, color, and appearance,
neither the participants nor the researchers knew which
capsule was administered.
All product formulations were supplied by Pipeline
Nutraceuticals, Inc. Fairfield, California, USA. All encap-
sulating, bottling and packaging was supplied by and
carried out by Protein Research, Inc., Livermore, Califor-
nia, USA.
During the study period, subjects were examined bi-
weekly. Their body weight, percent body fat, and waist/
hip circumferences were recorded, and serological analy-
sis was performed. Subjective impressions (e.g.,
increased/decreased appetite, feelings of lightness, gas-
trointestinal pains, etc.) were solicited and recorded dur-
ing each visit. The subjects were also asked about their
physical activity and food intake although no major diet-
ary changes or exercises were suggested.
Anthropometric measurements
Body weight, body fat, waist and hip circumference were
assessed at each visit with a Tanita™ BC-418 Segmental
Body Composition Analyzer/Scale that uses bio-
electrical impedance analysis for body composition ana-
lysis. Height was measured with a Harpended™ stadi-
ometer, which measures the length of curved line
staffage to the nearest 0.5 cm.
Participants (12-hour fasted) were encouraged to wear
light clothing before measurements were taken. Waist
and hip measures were obtained with a soft non-stretch-
able plastic tape. Waist circumference was measured on
the narrowest and the widest parts of the trunk; hip cir-
cumference was obtained at the widest point of the hip.
In an effort to ensure intra-individual consistency, the
participants were measured at approximately the same
time of day each visit.
Serological/Laboratory methods
Blood samples were collected after a 12-hour overnight
fast into heparinized tubes at the beginning of the study
and after 2, 4, 6, and 8 weeks of treatment. The concen-
trations of total cholesterol, LDL cholesterol, HDL cho-
lesterol, triglycerides, fasting blood glucose, serotonin,
C-reactive protein, and leptin were measured using
commercial diagnostic kits from SIGMA Diagnostics, St.
Louis, Missouri, USA.
Statistical Analysis
The data for each parameter were summarized (n, mean,
standard deviation) for Week 0 (Initial) and Week 8
(final) and for the intra-group percent differences. The
percent change from baseline was tested for differences
using the Mixed Effects Model, a flexible tool for analyz-
ing repeated and longitudinal treatments.
Results
Anthropomorphic characteristics (body weight, body fat,
waist size, hip size)
A ss h o w ni nT a b l e s1 ,2 ,3 ,a n d4 ,o v e rap e r i o do f8
weeks the two treatment groups (Formula A = low dose;
Formula B = high dose) showed a statistically significant
decrease compared to the placebo group on all four
variables. The only significant difference between the
two formulations was in body weight loss (see Table 1).
Body weight (Table 1)
Although the placebo group showed virtually no change
(0.82 kg) in body weight over the 8-week trial, the
Table 1 Body weight: effectiveness of treatments
Body Weight
(mean kg)
Weight
change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 100.93 ± 6.30 94.36 ± 5.67
b* -6.95
‡
Formula A (↓dose) 102.28 ± 7.17 97.04 ± 5.95
b -5.40
†
Placebo 101.32 ± 6.13 100.50 ± 7.28 -0.82
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
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mula B group lost 6.6 kg (p < 0.001). In terms of intra-
group mean-% change from baseline (Initial) to 8 weeks,
the placebo, Formula A and Formula B groups lost
0.82%, 5.4% (p < .05), and 6.95% (p < 0.001),
respectively.
Body fat (Table 2)
As with body weight, the placebo group showed little
(0.1%) change in mean %-body fat after 8 weeks whereas
the Formula A group lost 1.1% (p < 0.05), and
the Formula B group lost 1.8% (p < 0.05). In terms of
intra-group mean % change from baseline to 8 weeks, the
placebo, Formula A and Formula B groups lost 0.24%,
2.8% (p < 0.05), and 4.1% (p < 0.001), respectively.
Waist size (Table 3)
Waist circumference is one of the most important deter-
minants in the diagnosis of obesity and metabolic syn-
drome. In this case, the Formula A and Formula B
groups showed a 4.6 cm and 5.6 cm decrease,
respectively, vs. the 0.6 cm decrease demonstrated by
t h ep l a c e b og r o u p( p<0 . 0 5 ) .I nt e r m so fi n t r a - g r o u p
mean % change in waist size from baseline to 8 weeks,
the placebo, Formula A and Formula B groups lost
0.57%, 4.4% (p < 0.05), and 4.6% (p < 0.001),
respectively.
Hip size (Table 4)
Once again, although the placebo group showed virtually
no change (0.4 cm), the Formula A group lost 4.4 cm (p
< 0.05), and the Formula B group lost 5.6 cm (p < 0.05)
in circumference over the 8-week trial. In terms of intra-
group mean % change from baseline to 8 weeks, the pla-
cebo, Formula A and Formula B groups lost 0.32%, 3.5%
(p < .05), and 4.6% (p < 0.001), respectively.
Serological characteristics (total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, fasting blood
glucose, serotonin, leptin, C-reactive protein)
A ss h o w ni nT a b l e s5 ,6 ,7 ,8 ,9a n d1 0 ,t h et w ot r e a t -
ments (vs. placebo) groups showed a statistically signifi-
cant difference on all eight variables by the end of the
8-week trial period. There were significant differences
between the two formulations (in favour of the high
dosage Formula B) on triglyceride, blood glucose, sero-
tonin, and C-reactive protein levels.
Plasma total cholesterol level (Table 5)
In contrast to the small (4.5 mg/dL) reduction in total
cholesterol shown by the placebo group at 8 weeks,
the reduction for the Formula A group was 37.6 mg/dL
(p < 0.05), and that of the Formula B group was 57.9
mg/dL (p < 0.001). In terms of intra-group mean %
change from baseline (Initial) to 8 weeks, the placebo
group decrease was 2.1% whereas the Formula A and
Formula B groups decreases were 18.0% (p < 0.05) and
27.5 (p < 0.001), respectively.
Plasma LDL cholesterol level (Table 5)
As with total cholesterol level, the placebo group
showed a small (3.6 mg/dL) decrease in LDL cholesterol
by 8 weeks. This can be compared with the 24.0 mg/dL
reduction shown by the Formula A group (p < 0.05)
and the 32.8 mg/dL reduction of the Formula B group
(p < 0.001). In terms of intra-group mean % change in
LDL from baseline to 8 weeks, the placebo, Formula
A and Formula B groups decreased by 2.4%, 14.7%
(p < 0.05), and 19.8% (p < 0.001), respectively.
Plasma HDL cholesterol level (Table 5)
On one of the few variables where an increase in level is
desirable, the placebo group showed a very small (1.3
mg/dL) increase in HDL cholesterol at 8 weeks. This
can be compared with the 4.7 mg/dL increase shown by
Table 2 Body fat: effectiveness of treatments
Body fat (mean %) Fat reduction (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 43.85 ± 5.60 42.04 ± 6.63
a -4.13
‡
Formula A (↓dose) 40.22 ± 7.26 39.08 ± 6.12
a -2.83
†
Placebo 42.28 ± 8.27 42.18 ± 8.117 -0.24
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 3 Waist size: effectiveness of treatments
Waist circumference
(mean cm)
Waist
change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 110.50 ± 7.28 105.38 ± 10.64
a -4.64
‡
Formula A (↓dose) 104.00 ± 8.63 99.40 ± 11.73
a -4.42
†
Placebo 105.60 ± 7.91 105.00 ± 15.77 -0.57
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 4 Hip size: effectiveness of treatments
Hip circumference
(mean cm)
Hip
change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 123.38 ± 10.84 117.75 ± 17.24
a -4.56
‡
Formula A (↓dose) 126.20 ± 12.91 121.80 ± 15.41
a -3.49
†
Placebo 125.85 ± 14.72 125.45 ± 17.99 -0.32
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Kuate et al. Lipids in Health and Disease 2010, 9:20
http://www.lipidworld.com/content/9/1/20
Page 4 of 7the Formula A group (p < 0.05) and the 6.2 mg/dL
increase of the Formula B group (p < 0.001). In terms of
intra-group mean % change in HDL from baseline to 8
weeks, the placebo, Formula A and Formula B groups
increased by 3.6%, 13.6% (p < 0.05), and 19.1%
(p < 0.001), respectively.
Plasma triglyceride level (Table 6)
Per the above, the placebo group demonstrated a small
change (1.0 mg/dL decrease) in triglyceride level at the
end of the 8-week trial. This can be compared with the
11.5 mg/dL decrease shown by the Formula A group
Table 6 Plasma Triglyceride level: effectiveness of
treatments
Triglyceride (mean mg/dl) change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 167.61 ± 10.84 140.04 ± 4.29
b* -16.45
‡
Formula A (↓dose) 162.21 ± 12.95 150.71 ± 8.30
a -7.09
†
Placebo 168.93 ± 14.04 167.90 ± 10.30 -0.61
ap < 0.05;
bp < 0.001; compared with Placebo
*p < 0.05; **p < 0.001; compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 7 Fasting Blood Glucose levels: effectiveness of
treatments
Blood Glucose (mean mg/dl) change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 104.84 ± 9.39 92.06 ± 6.29
b* -12.19
‡
Formula A (↓dose) 105.61 ± 8.62 97.22 ± 7.81
a -7.94
†
Placebo 107.52 ± 8.73 105.90 ± 10.79 -1.51
ap < 0.05;
bp < 0.001; compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 5 Plasma Total Cholesterol, LDL cholesterol and HDL cholesterol levels: effectiveness of treatments
Time (weeks) % Change
Variable Group Initial 8 8 weeks - Initial
Total Cholesterol (mg/dl) Placebo 211.16 ± 11.92 206.68 ± 20.19 -2.12
Formula A (↓dose) 208.74 ± 10.49 171.17 ± 18.82
a -18.00
†
Formula B (↑dose) 210.64 ± 9.30 152.75 ± 10.19
b -27.48
‡
LDL Cholesterol (mg/dl) Placebo 166.21 ± 9.25 162.63 ± 17.83 -2.39
Formula A (↓dose) 163.94 ± 8.27 139.91 ± 8.92
a -14.66
†
Formula B (↑dose) 165.84 ± 7.29 133.05 ± 7.71
b -19.77
‡
HDL Cholesterol (mg/dl) Placebo 35.92 ± 5.16 37.22 ± 5.59 +3.62
Formula A (↓ dose) 34.72 ± 3.28 39.46 ± 4.48
a +13.65
†
Formula B (↑dose) 32.43 ± 2.10 38.63 ± 3.11
b +19.12
‡
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 8 Serum Serotonin levels: effectiveness of
treatments
Serotonin (mean mg/dl) change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 35.40 ± 2.62 49.06 ± 2.85
b* 38.59
‡
Formula A (↓dose) 34.55 ± 2.85 44.42 ± 2.96
a 28.57
‡
Placebo 34.20 ± 3.15 37.31 ± 3.69 9.09
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 9 Serum Leptin levels: effectiveness of treatments
Leptin (mean mg/dl) change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 30.15 ± 1.50 15.83 ± 1.13
b -47.59
‡
Formula A (↓dose) 31.52 ± 1.21 16.72 ± 1.40
a -46.95
‡
Placebo 30.33 ± 1.63 25.97 ± 1.61 -14.38
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001; compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
Table 10 C-Reactive Protein levels: effectiveness of
treatments
CRP (mean mg/l) change (%)
Initial 8 Weeks 8 Weeks - Initial
Formula B (↑dose) 11.58 ± 1.11 8.17 ± 0.61
b* -29.45
‡
Formula A (↓dose) 10.99 ± 1.26 9.33 ± 0.43
a -15.10
‡
Placebo 12.46 ± 1.30 12.05 ± 1.39 -3.31
ap < 0.05;
bp < 0.001 compared with Placebo
*p < 0.05; **p < 0.001 compared with Formula A
†p < 0.05;
‡p < 0.001 compared with Initial; intragroup analysis
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by the Formula B group (p < 0.001). In terms of intra-
group mean % change in triglyceride level from baseline
to 8 weeks, the placebo, Formula A and Formula B
groups decreased by 0.6%, 7.1% (p < 0.05), and 16.4%
(p < 0.001), respectively.
Fasting blood glucose levels (Table 7)
In contrast to the small (1.6 mg/dL) decrease in blood
glucose level shown by the placebo group at 8 weeks,
the reduction for the Formula A group was 8.4 mg/dL
(p < 0.05) and that of the Formula B group was 12.8
mg/dL (p < 0.001). In terms of intra-group mean %
change from baseline to 8 weeks, the placebo, Formula
A and Formula B groups decreased by 1.5%, 7.9%
(p < 0.05), and 12.9% (p < 0.001), respectively.
Serum serotonin levels (Table 8)
In another case (see HDL cholesterol above) where an
increase in level is desirable, the placebo group showed
a very small (1.6 mg/dL) increase in serotonin levels at
8 weeks. This can be compared with the 9.9 mg/dL
increase shown by the Formula A group (p < 0.05)
and the 13.7 mg/dL increase of the Formula B group
(p < 0.001). In terms of intra-group mean % change in
serotonin from baseline to 8 weeks, the placebo, For-
mula A and Formula B groups increased by 9.1%, 28.6%
(p < 0.001), and 38.6% (p < 0.001), respectively.
Serum leptin levels (Table 9)
In contrast to the 4.4 mg/dL decrease in serum
leptin levels shown by the placebo group at 8 weeks,
the reduction for the Formula A group was 14.8 mg/dL
(p < 0.05) and that of the Formula B group was 14.38
mg/dL (p < 0.001). In terms of intra-group mean %
change from baseline to 8 weeks, the placebo, Formula
A and Formula B groups decreased by 14.4%, 47.0%
(p < 0.001), and 48.0% (p < 0.001), respectively.
C-reactive protein levels (Table 10)
Per the above, the placebo group demonstrated a small
change (0.4 mg/l decrease) in C-reactive protein levels
at the end of the 8-week trial. This can be compared
with the 1.6 mg/l decrease shown by the Formula A
g r o u p( p<0 . 0 5 )a n dt h e3 . 4m g / lr e d u c t i o nd e m o n -
strated by the Formula B group (p < 0.001). In terms of
intra-group mean % change in blood levels of C-reactive
protein from baseline to 8 weeks, the placebo, Formula
A and Formula B groups decreased by 3.3%, 15.1% (p <
0.001), and 29.4% (p < 0.001), respectively.
Adverse events
Adverse events with an incidence >3 included lack of
sleep (4), and headache (4). Since the type and incidence
of all reported side effects were also observed in the pla-
cebo group, one can assume that the LeptiCore® formu-
lation had few, if any, negative side effects.
Discussion
Our results support the hypothesis that the use of Lepti-
Core®, a unique natural formulation, has considerable
efficacy on weight loss in patients with metabolic syn-
drome. Compared to the placebo group, the two active
groups (low and high dosage) showed statistically signifi-
cant differences on all 12 variables by the end of the 8-
week trial. Although there were no differences between
the two active groups on body fat, waist and hip size; or
cholesterol (total, HDL, LDL) or leptin levels, the higher
dosage did result in significantly greater reductions in
body weight, and triglyceride, blood glucose, CRP and
serotonin levels.
It appears that LeptiCore® somehow enhances cell
membrane stability for improved cellular communica-
tion between the liver and adipose tissues for enhanced
fatty acid utilization leading to regional fat loss. In addi-
tion, modulation of membrane-based inflammatory mar-
kers helped to reduce the inflammatory component of
fat gain. This is where this formulation differs from
other leptin-reducing supplements. Ingredients in this
proprietary blend not only lowered serum leptin levels
but also reduced CRP, a key marker for low grade
inflammation. As discussed earlier, some researchers
believe the binding of CRP to leptin may be the reason
[16]. The fact that CRP is elevated in obese people
increases the plausibility of their argument. CRP, which
is produced by the liver and typically rises as a part of
the immune system’s inflammatory response, has been
gaining favor as a marker for hypertension and heart
disease risk– both known complications of obesity.
LeptiCore’s efficacy may also be due to the fact that it
effects a time-dependent transit through the gastro-
intestinal tract which, in turn, elicits a signal to regulate
leptin levels. This is the mechanism for reducing the
level of leptin in the bloodstream and the corresponding
reduction in the percentage of body fat. LeptiCore’s abil-
ity to lower CRP levels allows the remaining circulating
leptin to reside in its “free” state and bind to appetite-
regulating leptin receptors in the hypothalamus.
Yet another aspect of LeptiCore’sa c t i o ni si t sp o t e n -
tial antioxidant power. The plasma concentrations of
leptin are markedly increased in human obesity and
positively correlated to body fat mass [26]. As human
obesity is associated with hyperleptinemia and athero-
sclerosis, it was shown that leptin, in addition to its
angiogenic properties, exerts proatherogenic effect on
endothelial cells by increasing reactive oxygen species
(ROS) formation. As mentioned earlier, Boulimie et al.
[11] have shown that the administration of leptin may
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human endothelial cells. Increases in oxidative stress in
the vascular endothelium may interact with nitric oxide
to form peroxynitrite and thereby decrease the bioavail-
ability of nitric oxide, which, in turn, could reduce
weight gain and food intake [27].
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